Effects of high-dose vitamin D2 versus D3 on total and free 25-hydroxyvitamin D and markers of calcium balance

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 8, 2016, Pages 3070-3078

  Shieh, Albert ^a   Chun, Rene F ^a   Ma, Christina ^b   Witzel, Sten ^a   Meyer, Briana ^a   Rafison, Brandon ^a   Swinkels, Leon ^c   Huijs, Tonnie ^c   Pepkowitz, Sam ^d   Holmquist, Brett ^d   Hewison, Martin ^e   Adams, John S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Future Diagnostics   (Netherlands)

^d Esoterix Inc   (United States)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PARATHYROID HORMONE; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; ARTICLE; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CALCIUM CREATININE RATIO; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UROGENITAL SYSTEM PARAMETERS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; HOMEOSTASIS; HORMONE SUBSTITUTION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VITAMIN D DEFICIENCY;

ADULT; AGED; BIOMARKERS; CALCIUM; CASE-CONTROL STUDIES; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; HOMEOSTASIS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PARATHYROID HORMONE; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84984685566     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1871     Document Type: Article

References (54)

1. HolickM.VitaminDdeficiency.NEngl JMed. 2007;357:266-281.
2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of Vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011; 96:1911-1930.
3. Park EA. The therapy of rickets. JAMA. 1940;115:370-379.
4. TrangHM,Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68:854-858.
5. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677-681.
6. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008;93:3015-3020.
7. Thacher TD, Obadofin MO, O'Brien KO, Abrams SA. The effect of vitamin D2 and vitamin D3 on intestinal calcium absorption in Nigerian children with rickets. J Clin Endocrinol Metab. 2009;94: 3314-3321.
8. Binkley N, Gemar D, Engelke J, et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. J Clin Endocrinol Metab. 2011;96:981-988.
9. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than Vitamin D(2) in humans. J Clin Endocrinol Metab. 2011;96:E447-E452.
10. Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of Vitamin D(2) and D(3) in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013;98:4339-4345.
11. Glendenning P, Chew GT, Inderjeeth CA, Taranto M, Fraser WD. Calculated free and bioavailable Vitamin D metabolite concentrations in Vitamin D-deficient hip fracture patients after supplementation with cholecalciferol and ergocalciferol. Bone. 2013;56:271-275.
12. Chun RF, Peercy BE, Orwoll ES, Nielson CM, Adams JS, Hewison M. Vitamin D and DBP: the free hormone hypothesis revisited. J Steroid Biochem Mol Biol. 2014;144PA:132-137.
13. Christensen EI, Birn H. Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule. Am J Physiol Renal Physiol. 2001;280:F562-F573.
14. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of Vitamin D: an Endocrine Society Scientific Statement. Endocr Rev. 2012;33:456-492.
15. Chun RF, Lauridsen AL, Suon L, et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy-and 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab. 2010;95:3368-3376.
16. Belsey R, Clark MB, Bernat M, et al. The physiologic significance of plasma transport of Vitamin D and metabolites. Am J Med. 1974; 57:50-56.
17. Jones G, Byrnes B, Palma F, Segev D, Mazur Y. Displacement potency of vitamin D2 analogs in competitive protein-binding assays for 25-hydroxyvitamin D3, 24,25-dihydroxyvitamin D3, and 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 1980;50:773-775.
18. Hollis B. Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their major metabolites. J Steroid Biochem. 1984;21:81-86.
19. Chun RF, Pereira R, Huijs T, et al. Differential effects of vitamin D2 vs. vitamin D3 on bone are associated with variations in free 25-hydroxyvitamin D. J Bone Miner Res. 2015;30. Available at http://www.asbmr.org/education/AbstractDetail?aid=4880c4877e-4200a-4884cb4889-ac4886e-4881e658604f658671. Accessed February 658628, 652016.
20. PoweCE, EvansMK,Wenger J, et al. Vitamin D-binding protein and Vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991-2000.
21. Schwartz JB, Lai J, Lizaola B, et al. A comparison of measured and calculated free 25(OH) Vitamin D levels in clinical populations. J Clin Endocrinol Metab. 2014;99:1631-1637.
22. Nielson CM, Jones KS, Bouillon R, et al. Role of assay type in determining free 25-hydroxyvitaminDlevels in diverse populations. N Engl J Med. 2016;374:1695-1696.
23. Nielson CM, Jones KS, Chun RF, et al. Free 25-hydroxyvitamin D: impact of Vitamin D binding protein assays on racial-genotypic associations. J Clin Endocrinol Metab. 2016;101:2226-2234.
24. Adams JS, Hewison M. Update in Vitamin D. J Clin Endocrinol Metab. 2010;95:471-478.
25. Adams JS, Kantorovich V, Wu C, Javanbakht M, Hollis BW. Resolution of Vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab. 1999;84:2729-2730.
26. Pepper KJ, Judd SE, Nanes MS, Tangpricha V. Evaluation of Vitamin D repletion regimens to correct Vitamin D status in adults. Endocr Pract. 2009;15:95-103.
27. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992; 327:1637-1642.
28. Hsu SA, Soldo J, Gupta M. Evaluation of two automated immunoassays for 25-OH Vitamin D: comparison against LC-MS/MS. J Steroid Biochem Mol Biol. 2013;136:139-145.
29. Horst R. Exogenous versus endogenous recovery of 25-hydroxyvitamins D2 and D3 in human samples using high-performance liquid chromatography and the DiaSorin LIAISON Total-D assay. J Steroid Biochem Mol Biol. 2010;121:180-182.
30. Freeman J, Wilson K, Spears R, Shalhoub V, Sibley P. Performance evaluation of four 25-hydroxyvitamin D assays to measure 25-hydroxyvitamin D2. Clin Biochem. 2015;48:1097-1104.
31. Aloia J, MikhailM,Dhaliwal R, et al. Free25(OH)Dand the Vitamin D paradox in African Americans. J Clin Endocrinol Metab. 2015; 100:3356-3363.
32. Aloia J, Dhaliwal R, Mikhail M, et al. Free 25(OH)D and calcium absorption, PTH, and markers of bone turnover. J Clin Endocrinol Metab. 2015;100:4140-4145.
33. Jones KS, Assar S, Harnpanich D, et al.25(OH)D2half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. J Clin Endocrinol Metab. 2014;99:3373-3381.
34. Schwartz JB, Kane L, Bikle D. Response of vitaminDconcentration to vitamin D3 administration in older adults without sun exposure: a randomized double-blind trial. J AmGeriatr Soc. 2016;64:65-72.
35. Swanson CM, Nielson CM, Shrestha S, et al. Higher 25(OH)D2 is associated with lower 25(OH)D3 and 1,25(OH)2D3. J Clin Endocrinol Metab. 2014;99:2736-2744.
36. Tsugawa N, Nakagawa K, Kawamoto Y, et al. Biological activity profiles of 1,25-dihydroxyvitamin D2, D3, D4, D7, and 24-epi-1,25-dihydroxyvitamin D2. Biol Pharm Bull. 1999;22:371-377.
37. Delmez JA, Tindira C, Grooms P, Dusso A, Windus DW, Slatopolsky E. Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium. J Clin Invest. 1989;83:1349-1355.
38. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the Vitamin D-bone mineral density relationship. J Bone Miner Res. 2011;26:1609-1616.
39. Bhan I, Powe CE, Berg AH, et al. Bioavailable Vitamin D is more tightly linked to mineral metabolism than total vitaminDin incident hemodialysis patients. Kidney Int. 2012;82:84-89.
40. Jemielita TO, Leonard MB, Baker J, et al. Association of 25-hydroxyvitaminDwith areal and volumetric measures of bone mineral density and parathyroid hormone: impact of Vitamin D-binding protein and its assays. Osteoporos Int. 2016;27:617-626.
41. Sollid ST, Hutchinson MY, Berg V, et al. Effects of Vitamin D binding protein phenotypes and Vitamin D supplementation on serum total 25(OH)D and directly measured free 25(OH)D. Eur J Endocrinol. 2016;174:445-452.
42. Goswami R, Saha S, Sreenivas V, Singh N, Lakshmy R. Vitamin D-binding protein, Vitamin D status and serum bioavailable 25(OH)D of young Asian Indian males working in outdoor and indoor environments [published online January 30, 2016]. J Bone Miner Metab. doi: 10.1007/s00774-016-0739-x.
43. Bienaimé F, Prié D, Friedlander G, Souberbielle J. Vitamin D metabolism and activity in the parathyroid gland. Mol Cell Endocrinol. 2011;347:30-41.
44. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1-hydroxylase. J Clin Endocrinol Metab. 2001;86:888-894.
45. Zehnder D, Bland R, Chana RS, et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol. 2002;13:621-629.
46. Hewison M, Burke F, Evans KN, et al. Extra-renal 25-hydroxyvitamin D3-1-hydroxylase in human health and disease. J Steroid Biochem Mol Biol. 2007;103:316-321.
47. Vanhooke JL, Prahl JM, Kimmel-Jehan C, et al. CYP27B1 null mice with LacZreporter gene display no 25-hydroxyvitamin D3-1-hydroxylase promoter activity in the skin. Proc Natl Acad Sci USA. 2006;103:75-80.
48. Hewison M, Kantorovich V, Liker HR, et al. Vitamin D-mediated hypercalcemia in lymphoma: evidence for hormone production by tumor-adjacent macrophages. J Bone Miner Res. 2003;18:579-582.
49. Segersten U, Correa P, Hewison M, et al. 25-Hydroxyvitamin D(3)-1-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab. 2002;87:2967-2972.
50. Silver J, Russell J, Sherwood L. Regulation by vitaminDmetabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA. 1985; 82:4270-4273.
51. Canterbury JM, Lerman S, Claflin AJ, Henry H, Norman A, Reiss E. Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog. J Clin Invest. 1978;61:1375-1383.
52. Lundgren S, Carling T, Hjälm G, et al. Tissue distribution of human gp330/megalin, a putative Ca(2α)-sensing protein. J Histochem Cytochem. 1997;45:383-392.
53. Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistance to Vitamin D toxicity in mice null for Vitamin D binding protein. J Clin Invest. 1999;103:239-251.
54. Kantorovich V, Gacad MA, Seeger LL, Adams JS. Bone mineral density increases with vitaminDrepletion in patients with coexistent Vitamin D insufficiency and primary hyperparathyroidism. J Clin Endocrinol Metab. 2000;85:3541-3543.